| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 514254030 | The additional five-membered hetero ring consists of two ring carbons, two ring nitrogens, and one ring chalcogen (e.g., oxadiazolyl, thiadiazolyl, etc.) | 21 |
| 20080255147 | Heterocycles useful as modulators of ion channels - The present invention relates to compounds useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders. | 10-16-2008 |
| 20080261996 | Substituted propiolic acid amides and their use for producing drugs - The present invention relates to substituted propiolic acid amides, methods for the production thereof, medicaments containing these compounds and the use thereof for producing medicaments. | 10-23-2008 |
| 20080306088 | Metabotropic Glutamate Receptor Oxadiazole Ligands and Their Use as Potentiators 841 - Compounds of Formula I: | 12-11-2008 |
| 20090264441 | Compounds, Compositions and Methods Comprising Oxadiazole Derivatives - The present invention relates to compositions and methods for treating a disease in an animal, which disease is responsive to inhibiting of functional cystic fibrosis transmembrane conductance regulator (CFTR) polypeptide by administering to a mammal in need thereof an effective amount of a compound defined herein (including those compounds set forth in Tables 1-2 or encompassed by formulas I-IV) or compositions thereof, thereby treating the disease. The present invention particularly, relates to a method of treating diarrhea and polycystic kidney disease. | 10-22-2009 |
| 20100048587 | CYSTEINE AND CYSTINE BIOISOSTERES TO TREAT SCHIZOPHRENIA AND REDUCE DRUG CRAVINGS - The present invention provides cysteine and cystine bioisosteres for the treatment of schizophrenia and drug addiction. The invention further encompasses pharmaceutical compositions containing such bioisosteres and methods of using the bioisosteres for treatment of schizophrenia and drug addiction. | 02-25-2010 |
| 20100267740 | Oxadiazole Derivatives and Their Use as Metabotropic Glutamate Receptor Potentiators - 842 - Compounds of Formula (I) wherein R | 10-21-2010 |
| 20110046154 | USE OF AMINOPEPTIDASE INHIBITORS OR AZAINDOLE COMPOUNDS FOR PREVENTING OR TREATING CANCEROUS METASTASES FROM EPITHELIAL ORIGIN - The invention relates to the use of a compound selected from an aminopeptidase-inhibiting compound and an azaindole compound for producing a drug for preventing or treating cancerous metastases in humans or animals. | 02-24-2011 |
| 20110059984 | HETEROCYCLES USEFUL AS MODULATORS OF ION CHANNELS - The present invention relates to compounds useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders. | 03-10-2011 |
| 20110105524 | CYSTEINE PROTEASE INHIBITORS - Compounds of the formula II: | 05-05-2011 |
| 20110136823 | COMPOUNDS HAVING A POTENTIATING EFFECT ON THE ACTIVITY OF ETHIONAMIDE AND USES THEREOF - The present invention relates to the use of compounds with a potentiating effect on the activity of antibiotics that are activatable via the EthA enzymatic pathway, for the preparation of a medicament for preventing and/or treating mycobacterial infections such as tuberculosis and leprosy, to pharmaceutical compositions comprising them in combination with an antibiotic that is activatable via the EthA pathway, to compounds having a potentiating effect on the activity of antibiotics that are activatable via the EthA enzymatic pathway, to pharmaceutical compositions comprising them and to their use as medicaments, especially medicaments for preventing and/or treating mycobacterial infections such as tuberculosis and leprosy. | 06-09-2011 |
| 20110166155 | Substituted Isoindolones and Their Use as Metabotropic Glutamate Receptor Potentiators - The present invention is directed to compounds of formula I: | 07-07-2011 |
| 20110212974 | METHOD FOR IDENTIFYING COMPOUNDS USEFUL FOR TREATING AND/OR PREVENTING DISEASE-ASSOCIATED BONE LOSS - The present invention concerns a method for identifying a compound which inhibits the activation of RAC GTPase by DOCK5 protein comprising the steps of (i) coexpressing the DOCK5 and the RAC proteins in a cell, wherein said DOCK5 protein induces the conversion of inactive RAC, which inactive RAC is bound to GDP, to active RAC, which active RAC is bound to GTP, (ii) contacting or not said cell with said compound, (iii) determining the conversion of inactive RAC to active RAC in the presence or absence of said compound, and (iv) selecting the compound inhibiting the conversion of inactive RAC to active RAC. Said compound is useful for treating disease-associated bone loss. | 09-01-2011 |
| 20110275649 | Combination therapy for the prevention of statin induced diabetes - Novel combinations comprising HMG CoA reductase inhibitors, or statins, with partial fatty acid oxidation inhibitors (pFOXi), and methods for their use, are disclosed. These combinations are useful in preventing or reducing the risk of developing diabetes which results from therapy with a statin. | 11-10-2011 |
| 20110288103 | COMPOUNDS, COMPOSITIONS, AND METHODS COMPRISING 1,3,4-OXADIAZOLE DERIVATIVES - The present invention relates to methods for treating a disease in an animal, which disease is responsive to blocking of calcium activated chloride echannel (CaCC) by administering to a mammal in need thereof an effective amount of a compound defined herein (including those compounds set forth in Tables 1-2 or encompassed by formulas I-IV) or compositions thereof, thereby treating the disease. | 11-24-2011 |
| 20120088779 | HETEROCYCLIC SULFONAMIDES - Certain substituted sulfonamide derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure. | 04-12-2012 |
| 20120136003 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING 1,3,4-OXADIAZOLE DERIVATIVES - The present invention relates to compositions and methods for treating a disease in an animal, which disease is responsive to inhibiting of functional cystic fibrosis transmembrane conductance regulator (CFTR) polypeptide by administering to a mammal in need thereof an effective amount of a compound defined herein (including those compounds set forth in Tables 1-2 or encompassed by formulas I-IV) or compositions comprising these compounds, thereby treating the disease. The present invention particularly, relates to a method of treating diarrhea and polycystic kidney disease. | 05-31-2012 |
| 20120142700 | MICROBIOCIDAL HETEROCYCLES - The present invention relates to heterocyclic compounds of formula (I) which have microbiocidal activity, in particular fungicidal activity, as well as methods of using the compounds of formula (I) to control microbes. | 06-07-2012 |
| 20120232092 | HETEROCYCLIC SULFONAMIDES - Certain substituted sulfonamide derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure. | 09-13-2012 |
| 20130237548 | INJECTABLE EMULSION OF SEDATIVE HYPNOTIC AGENT - Polymorphs of 7-methyl-5-(3-piperazin-1-ylmethyl-[1,2,4]oxadiazol-5-yl)-2-(4-trifluoromethoxybenzyl)-2,3-dihydroisoindol-1-one mesylate salt, methods of making these polymorphs and uses thereof. | 09-12-2013 |
| 20130267537 | HETEROCYCLIC SULFONAMIDES - Certain substituted sulfonamide derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure. | 10-10-2013 |
| 20140024656 | [1,3,4] OXADIAZOLE DERIVATIVE AND APPLICATION THEREOF - The present invention belongs to the medicinal chemistry field, and specifically discloses a [1,3,4]oxadiazole derivative with the structure of general formula (I) and pharmaceutically acceptable salt thereof. The compound can be used to prepare a medicine for preventing or treating a disease of the central nervous system. | 01-23-2014 |
